Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK Interaction of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers
NCT04598542Phase 1Completed
- Sponsor
- Biosplice Therapeutics
- Start
- Oct 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lorecivivint in knee osteoarthritis (OA) (2 arms), sponsored by Biosplice Therapeutics. Primary endpoints: Maximum Plasma Concentration (Cmax) of Lorecivivint, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC 0-last) of Lorecivivint and 4 more. Started Oct 2020; status: completed.
02
Drugs
lorecivivint
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04598542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04598542.